<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2017103037093N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2017-11-20</date_registration>
      <primary_sponsor>Vice chancellor for research, Shahrekord University of Medical Sciences</primary_sponsor>
      <public_title>Chicory gel effect on the treatment of osteoarthritis</public_title>
      <acronym></acronym>
      <scientific_title>comparsion of the effects of 3% Cichorium intybus L. hydroalcoholic extract gel vs diclofenac gel in the treatment of patients with primary monoarticular knee osteoarthritis who are taking celecoxib.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-12-03</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>150</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/27533</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization was done using random numbers table and statistical software, Blinding description: The gel tubes were prepared by the pharmacist and were labeled A, B, and C. None of the patients and researchers knew about their content.</study_design>
      <phase>3</phase>
      <hc_freetext>Knee osteoarthritis.</hc_freetext>
      <i_freetext>Intervention 1: Negative control group: Patients with primary monoarticular osteoarthritis of knee joint who take  200 mg celecoxib tablets once a day and use the gel containing the base of the gel (placebo) three times a day each time for 3 to 5 minutes for 6 Weeks over the involved area. Intervention 2: Positive control group: Patients with primary monoarticular osteoarthritis of knee joint who take  200 mg celecoxib tablets once a day, and use 1% diclofenac gel three times a day each time for 3 to 5 minutes  for 6 weeks  over the involved area. Intervention 3: Intervention group: Patients with primary monoarticular osteoarthritis of knee joint who take  200 mg celecoxib tablets once a day and use 3% chicory gel three times a day for 3 to 5 minutes for 6 weeks over the involved area.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information about the main outcome can be shared.

When:
Start the access period 4 months after publishing the results

To whom:
Researchers working in academia

Conditions:
Use data to complete clinical trial studies

Where to obtain:
Kashani Hospital in Shahrekord, dehghan_mortaza@yahoo.com

How to obtain:
after the investigation of resercher request and presentation of required documents will be accessible.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Morteza Dehghan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahrekord University of Medical Sciences, Building No. 2, University headquarters, Ayatollah Kashani Blvd</address>
        <city>Shahrekord</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8815713471</zip>
        <telephone>+98 38 3227 4004</telephone>
        <email>dehghan_mortaza@yahoo.com</email>
        <affiliation>Shahrekord University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Morteza Dehghan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahrekord University of Medical Sciences, Building No. 2, University headquarters, Ayatollah Kashani Blvd</address>
        <city>Shahrekord</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8815713471</zip>
        <telephone>+98 38 3227 4004</telephone>
        <email>dehghan_mortaza@yahoo.com</email>
        <affiliation>Shahrekord University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>age of 40-80 years
weight of 50-80 kgs
primary osteoarthritis in one knee, confirmed by radiological criteria in knee graphy
secondary osteoarthritis or suspecting to it
lack of history of cognitive impairment
lack of  Liver,kidney or any other underlying disease
having no history of allergies</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>primary osteoarthritis in both knees
history of allergy to any form of anti-inflammatory drugs
skin diseases,infection or ulcers at the site of topical use of the drug
use of other topical drugs at the place of use of the drug
use of aromatase inhibitors
the oral administration of other analgesics and other compounds effective in the treatment of osteoarthritis up to 10 days before the start of the study
congenital joint diseases
pregnancy
lack of cooperation and desire of the individual during the study to continue the company
creation of any Sensitivity or any problem during the intervention</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other primary gonarthrosis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Placebo</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Negative control group: Patients with primary monoarticular osteoarthritis of knee joint who take  200 mg celecoxib tablets once a day and use the gel containing the base of the gel (placebo) three times a day each time for 3 to 5 minutes for 6 Weeks over the involved area.</i_keyword>
      <i_keyword>Positive control group: Patients with primary monoarticular osteoarthritis of knee joint who take  200 mg celecoxib tablets once a day, and use 1% diclofenac gel three times a day each time for 3 to 5 minutes  for 6 weeks  over the involved area.</i_keyword>
      <i_keyword>Intervention group: Patients with primary monoarticular osteoarthritis of knee joint who take  200 mg celecoxib tablets once a day and use 3% chicory gel three times a day for 3 to 5 minutes for 6 weeks over the involved area.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Knee pain. Timepoint: Before intervention, 6 weeks after intervention. Method of measurement: Western Ontario &amp; McMaster Universities Osteoarthritis Index &amp; Visual Analogue Scale questionnaire.</prim_outcome>
      <prim_outcome>Daytime stiffness. Timepoint: Before intervention, 6 weeks after intervention. Method of measurement: Western Ontario &amp; McMaster Universities Osteoarthritis Index questionnaire.</prim_outcome>
      <prim_outcome>Morning stiffness. Timepoint: Before intervention, 6 weeks after intervention. Method of measurement: Western Ontario &amp; McMaster Universities Osteoarthritis Index questionnaire.</prim_outcome>
      <prim_outcome>Physical performance. Timepoint: Before intervention, 6 weeks after intervention. Method of measurement: Western Ontario &amp; McMaster Universities Osteoarthritis Index questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Skin allergy. Timepoint: Six weeks after the intervention. Method of measurement: Observation and examination.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for research, Shahrekord University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-10-29</approval_date>
        <contact_name>Ethics Committee of Shahrekord University of Medical Sciences</contact_name>
        <contact_address>Vice chancellor for research, Building No. 2, University headquarters, Ayatollah Kashani Blvd Shahrekord Chahar-Mahal-va-Bakhtiari Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
